The clinical implementation of circulating lncRNA HCC biomarkers, either by quantifying multiple-lncRNA panels alone or in combination with other biomarkers such as miRNAs and/or AFP, may drastically impact the assessment of HCC disease in the near future. Here, AFP is linked to hepatocellular carcinoma.